Eaton Vance Management Ligand Pharmaceuticals Inc Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Eaton Vance Management holds 5,000 shares of LGND stock, worth $424,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,000

Previous 5,025 0.5%

Holding current value

$424,250

Previous $448,000 3.79%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.01 - $107.56 $0 - $2,689	-25 Reduced 0.5%	5,000 $431,000
Q2 2022 Aug 15, 2022	SELL	$74.52 - $117.06 $49,257 - $77,376	-661 Reduced 11.63%	5,025 $448,000
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $32,961 - $52,591	-347 Reduced 5.75%	5,686 $639,000
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $7,661 - $9,951	60 Added 1.0%	6,033 $772,000
Q3 2021 Nov 15, 2021	BUY	$102.33 - $144.73 $46,867 - $66,286	458 Added 8.3%	5,973 $697,000

Q2 2021 Aug 16, 2021	BUY	$113.03 - $155.64 $52,558 - $72,372	465 Added 9.21%	5,515 $724,000
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $33.3 Million - $72.2 Million	-334,616 Reduced 98.51%	5,050 $770,000
Q4 2020 Feb 12, 2021	BUY	$80.55 - $106.05 $8.11 Million - $10.7 Million	100,710 Added 42.15%	339,666 $33.8 Million
Q3 2020 Nov 13, 2020	BUY	$89.56 - $126.72 $2.2 Million - $3.11 Million	24,512 Added 11.43%	238,956 $22.8 Million
Q2 2020 Aug 13, 2020	BUY	$68.28 - $123.65 $2.06 Million - $3.72 Million	30,104 Added 16.33%	214,444 $24 Million
Q1 2020 May 14, 2020	BUY	$63.37 - $107.88 $875,646 - $1.49 Million	13,818 Added 8.1%	184,340 $13.4 Million
Q4 2019 Feb 11, 2020	BUY	$96.94 - $113.59 $3.57 Million - $4.18 Million	36,787 Added 27.51%	170,522 $17.8 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $1.33 Million - $1.85 Million	15,428 Added 13.04%	133,735 $13.3 Million
Q2 2019 Aug 16, 2019	BUY	$107.38 - $129.34 $5.11 Million - $6.16 Million	47,614 Added 67.35%	118,307 $13.5 Million
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $51,799 - $69,667	-489 Reduced 0.69%	70,693 $8.89 Million
Q4 2018 Feb 07, 2019	BUY	$128.36 - $272.13 $1.23 Million - $2.61 Million	9,605 Added 15.6%	71,182 $9.66 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $3.13 Million - $4.07 Million	-14,812 Reduced 19.39%	61,577 $16.9 Million
Q2 2018 Aug 10, 2018	SELL	$150.77 - $207.98 $4.79 Million - $6.61 Million	-31,778 Reduced 29.38%	76,389 $15.8 Million
Q1 2018 May 07, 2018	SELL	$138.63 - $182.62 $4.42 Million - $5.82 Million	-31,877 Reduced 22.76%	108,167 $17.9 Million
Q4 2017 Feb 12, 2018	SELL	$128.36 - $147.04 $5.63 Million - $6.45 Million	-43,888 Reduced 23.86%	140,044 $19.2 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $22.2 Million - $25.4 Million	183,932	183,932 $25 Million

Others Institutions Holding LGND

# of Institutions

234

Shares Held

16.5M

Call Options Held

77.9K

Put Options Held

25K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.43B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Ligand Pharmaceuticals Inc Transaction History